EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights

Rita Balsano iD, Valentina Zanuso, Angelo Pirozzi, Lorenza Rimassa iD, Silvia Bozzarelli iD

Current Oncology · 30.03.2023 · 30 (4) · 3871-3885

DOI: 10.3390/curroncol30040293 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 30.03.2023. Verfasst von Rita Balsano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor 5-year overall survival rate (~10%). The revolution of immunotherapy in clinical oncology has not substantially changed clinical outcome for patients with PDAC. Despite outstanding efforts, neither immune checkpoint inhibitors (ICIs) alone, nor in combination with chemotherapy or targeted therapies have shown encouraging results. This failure mirrors the lack of knowledge about the real key players of immune system senescence and the complexity of the tumor microenvironment in PDAC. However, some hope can be derived from PARP-inhibitor combinations, vaccines, and CAR-T-cells therapy. In this review, we comprehensively summarize the latest updates about the use of ICIs in PDAC, focusing on clinical evidence and ongoing studies highlighting explanations for the failure of immunotherapy and possible solutions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

CAR-T cellsCTLA-4ICIsPARPPD-1PD-L1PDACimmunotherapyvaccines

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.

ORCID-Profile: Rita Balsano, Lorenza Rimassa, Silvia Bozzarelli

Zitieren

APA

Balsano, R., Zanuso, V., Pirozzi, A., Rimassa, L., & Bozzarelli, S. (2023). Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Current Oncology, 30(4), 3871-3885. https://doi.org/10.3390/curroncol30040293

Vancouver

Balsano R, Zanuso V, Pirozzi A, Rimassa L, Bozzarelli S. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. Current Oncology. 2023;30(4):3871-3885. doi:10.3390/curroncol30040293

BibTeX
@article{Balsano2023,
  author = {Balsano, Rita and Zanuso, Valentina and Pirozzi, Angelo and Rimassa, Lorenza and Bozzarelli, Silvia},
  title = {Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights},
  journal = {Current Oncology},
  year = {2023},
  volume = {30},
  number = {4},
  pages = {3871--3885},
  doi = {10.3390/curroncol30040293}
}
Kostenlos starten →